JYNTHealthcare · Medical Care FacilitiesThe 4 Wall Street analysts covering The Joint Corp. (United States) hold a median 12-month price target of $9 — +6.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores The Joint Corp. (United States) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (22): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JYNT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Aug 2025 | B. Riley Securities | Maintains | Buy | $20 → $18 |
| 8 Aug 2025 | B. Riley Securities | Maintains | Buy | — |
| 9 May 2025 | Lake Street | Maintains | Buy | — |
| 8 Nov 2024 | Roth MKM | Maintains | Buy | — |
| 6 May 2024 | B. Riley Securities | Maintains | Buy | — |
| 3 May 2024 | Roth MKM | Reiterates | Buy | — |
| 14 Sept 2023 | Roth MKM | Maintains | Buy | — |
| 11 Aug 2023 | Maxim Group | Downgrade | Hold | — |
| 11 Aug 2023 | Roth MKM | Maintains | Buy | — |
| 13 Mar 2023 | DA Davidson | Upgrade | Neutral | — |
| 8 Aug 2022 | DA Davidson | Maintains | Underperform | — |
| 5 Aug 2022 | B. Riley Securities | Upgrade | Buy | — |
| 5 Aug 2022 | Maxim Group | Upgrade | Buy | — |
| 10 May 2022 | DA Davidson | Downgrade | Underperform | — |
| 9 May 2022 | DA Davidson | Downgrade | Underperform | — |
| 6 May 2022 | Craig-Hallum | Downgrade | Hold | — |
| 25 Feb 2022 | DA Davidson | Maintains | Buy | — |
| 9 Aug 2021 | DA Davidson | Maintains | Buy | — |
| 6 Aug 2021 | Roth Capital | Maintains | Buy | — |
| 28 June 2021 | Roth Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JYNT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, The Joint Corp. (United States) returned −17.7% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 52% of US stocks
Cheaper than 13% of US stocks
Cheaper than 12% of US stocks
Higher than 61% of US stocks
Higher than 96% of US stocks
Higher than 93% of US stocks
Higher than 51% of US stocks
Higher than 63% of US stocks
Higher than 65% of US stocks
Higher than 61% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
The Joint Corp. (United States) has a market value of $119.4M and an enterprise value of $94.7M.
Revenue in the twelve months to 30 June 2026: $58.5M. The latest quarter grew 14.4% year on year.
Net income over the same four quarters: $3.8M, a 6.5% net margin.
Diluted earnings per share, trailing twelve months: $0.27.
Free cash flow in the twelve months to 30 June 2026: $4.2M.
The Joint Corp. (United States) spent $13.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 60.3×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.
The Joint Corp. (United States) employs 202 people — $290K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Joint Corp. (United States) — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of The Joint Corp.'s Q2 2026 earnings call. The item reports the availability of the call's full discussion and commentary.
Why it matters — The transcript gives JYNT watchers direct access to management's own account of the quarter's results and outlook.
The Joint Corp. reported second-quarter results that showed progress in its shift toward a capital-light, pure-play franchisor model. Management also said patient retention improved to its highest level in more than five years.
Why it matters — For JYNT watchers, the reported progress on its franchise-focused strategy and the improvement in patient retention point to the company's operational momentum in its core business.
The Joint Corp. (JYNT) reported a Q2 loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.11 per share. The loss narrowed compared to the $0.06 per share loss reported a year ago.
Why it matters — A JYNT watcher would note that the company's quarterly earnings fell short of analyst expectations, extending a pattern of losses.
The Joint Corp. has been named by Entrepreneur as one of its Top Brands for Multi-Unit Owners for 2026, recognizing the company as a premier growth opportunity for experienced multi-unit and multi-brand investors.
Why it matters — The recognition signals to JYNT watchers that the company's franchise model continues to gain credibility and traction among experienced investors in the healthcare franchise space.
The 4 Wall Street analysts covering The Joint Corp. (United States) have a median 12-month price target of $9, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering The Joint Corp. (United States), 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Joint Corp. (United States) 88 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, The Joint Corp. (United States) ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +6.6% from the last close, and Ticker Nerd's factor model ranks The Joint Corp. (United States) 88 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Joint Corp. (United States) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JYNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.
The Joint Corp. (United States) returned -17.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
The Joint Corp. is a healthcare services company that operates and franchises chiropractic clinics across the United States through The Joint Chiropractic brand.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "The Joint Corp. (JYNT) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of The Joint Corp.'s Q2 2026 earnings call. The item reports the availability of the call's full discussion and commentary.
The Joint Corp. is a healthcare services company that operates and franchises chiropractic clinics across the United States through The Joint Chiropractic brand. The company focuses on providing walk-in, appointment-free care for patients seeking relief from musculoskeletal pain and ongoing wellness support. Its clinics use a private-pay, non-insurance model that is designed to make chiropractic services more accessible and convenient for routine visits. The Joint Corp. serves consumers through a network that includes company-operated locations and franchised clinics, with services supported by membership-based wellness plans and standardized clinic operations. Headquartered in Scottsdale, Arizona, The Joint Corp. plays a significant role in the retail chiropractic market by combining local clinic access with a scalable franchising model.
CEO Mr. Sanjiv Razdan · 202 employees · United States · https://www.thejoint.com
